Evaluation Cervista and MALDI-TOF-MS for HPV Assay in Cervical Cancer Screening
DU Hui,WU Rui-fang,LI Jing-jing,YANG Bin,LIU Ying,ZHANG Li-jie,Belinson SE,WU Ruo-song,WAN Hong,QU Xin-feng,Belinson JL
DOI: https://doi.org/10.16458/j.cnki.1007-0893.2010.03.015
2010-01-01
Abstract:Objective The major study purpose of SHENCCASTⅡ(The Shenzhen Cervical Cancer Screening TrialⅡ)is to evaluate the feasibility of HPV as a primary cervical cancer screening based population.We report an interim evaluation of the new Cervista assay and MAILDI-TOF-MS for detection of HPV infection compared to HC-Ⅱ.Methods Women from Shenzhen urban,suburban and rural areas around the city were eligible if non-pregnant,25-59 yrs of age,no screening in 3 years,no hysterectomy,and no pelvic radiation.Cytology,HC-Ⅱ,the Cervistaassay,and MAILDI-TOF-MSwere all processed in that order from the same 20mL Preserv Cyt specimen,collected using thebroomsampler.Any patient with≥ASCUS,positive on any other HPV test was requested to further examination colposcopy and four-quadrant biopsy plus ECC.Results 5043 women had all results.14.6%(736)were HC-Ⅱpositive,12.2%(617)were Cervista positive,and 14%(705)were MAILDI-TOF-MS positive.3.0%(150)had≥CIN 2,1.9%(97)≥CIN 3,0.10%(5)with cancer.ForCIN2,the sensitivity,specificity PPV and NPV values for HC-Ⅱwere 94.7%,87.9%,19.3%and 99.8%respectively,that of Cervista were 90.7%,90.2%,22%and 99.7%and that of MAILDI-TOF-MS were 92.7%,88.4%,19.7%and 99.8%.ForCIN3,HC-Ⅱwere 97%,87%,12.8%and 99.9%,Cervista were 91.8%,89.3%,14.4%and 99.8%and MAILDITOF-MS were 94.9%,87.6%,13.1%and 99.9%.Compared with results of cervista,the sensitivity and specificity of HC-Ⅱand MAILDI-TOF-MS were siginificantly different(P0.01),and it have no significantly different between MAILDI-TOF-MS and HC-Ⅱ.Conclusion It is feasible for HPV as a primary cervical cancer screening based wide-scale population.High through-put,Type-specific data,low consumable cost and high sensitivity makes the MAILDI-TOF-MS potentially a more cost efficient approach.